Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
McFarland, L. V.; Bernasconi, P. (2011)
Publisher: Microbial Ecology in Health and Disease
Journal: Microbial Ecology in Health and Disease
Languages: English
Types: Article

Classified by OpenAIRE into

mesheuropmc: digestive, oral, and skin physiology
Saccharomyces boulardii is a non-pathogenic yeast which has been used as both a preventive and therapeutic agent for the treatment of a variety of diarrhoeal diseases. The studies with animal models and evidence from human volunteers and patients indicate a profile which is effective in the therapy of diarrhoea and is remarkably safe for oral ingestion. The pharmacokinetic data demonstrate that S. boulardii reaches a steady-state concentration quickly and maintains a high stable level as long as the yeast is taken daily. Once the agent is discontinued, S. boulardii is quickly eliminated from the colon. Clinical trials studying antibiotic-associated diarrhoea, nasogastric-tube alimentation diarrhoea, Clostridium difficile-disease, acute diarrhoea and chronic diarrhoea in HI V-infected patients are reviewed.Keywords - Saccharomyces boulardii; Biotherapeutic agent; Clostridium difficile; Diarrhoea.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Adam J, Barret A, Barret-Bellet C, et al. (1977). Essais cliniques contrdlks en double insu de l'ultralevure lyophilisee. Etude multicentrique par 25 mkdecins de 388 cas. Gazette Medicale de France 84, 2072-2078.
    • 2. Aronsson B, Molby R, Nord CE. (1985). Antimicrobial agents and Clostridium dzficile in acute enteric disease: epidemiological data from Sweden. Journal of Infectious Diseases 151,476-48 I .
    • 3 . Bartlett JG. (1992). Antibiotic-associated diarrhea. Clinical Infectious Diseases 15,573-58 I .
    • 4. Berg R, Bernasconi P, Fowler D, Gautreaux M. (1993). Inhibition of Candida albicans translocation from the gastrointestinal tract of immunosuppressed mice by oral treatment with Saccharomyces boulardii. Journal oflrtfectious Diseases (in press).
    • 5 . Blehaut H, Massot J, Elmer GW, Levy RH. (1989). Disposition kinetics of Saccharomyces boulardii in man and rat. Biopharmaceutics & Drug Disposition 10,353-364.
    • 6. Blehaut H, Saint-Marc T, Touraine JL. (1992). Double blind trial of Saccharomyces boulardii in AIDS related diarrhea. Abstract No. 2120, VIII International Conference on AIDS/III STD World Congress, 19-24 July.
    • 7. Boddy AV, Elmer GW, McFarland LV, Levy RH. (1991). Influence of antibiotics on the recovery and kinetics of Saccharomyces boulardii in rats. Pharmaceutical Research 8,796-800.
    • 8. Bowden TA, Mansberger AR, Lykins LE. (1982). Pseudomembraneous enterocolitis: mechanism of restoring floral hemeostasis. American Surgeon 4, I 78- 183.
    • 9. Buts J-P, Bernasconi P, Van Craynest M-P, Maldague P, De Meyer R. (1986). Response of human and rat smallintestinal mucosa to oral administration of Saccharomyces boulardii. Pediatric Research 20, 192-196.
    • 10. Buts J-P, Bernasconi P, Vaerman J-P, Dive C. ( I 990). Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Digestive Diseases and Sciences 35,251-256.
    • 11. Buts J-P, Corthier G, Delmee M. (1993). Saccharomyces boulardii for Clostridium dificile associated enteropathies in infants. Journal of Pediatric Gastroenterology and Nutrition (in press).
    • 12. Caetano JA, Parames MT, Babo MJ, Santos A, Ferreira AB, Freitas AA, Coelho MRC, Mateus AM. ( I 986). Immunopharmacological effects of Saccharomyces boulardii in healthy human volunteers. International Journal of Immunopharmacology 8,245-259.
    • 13. Can0 N, Chapoy P, Corthier G . (1989). Saccharomyces boutardii: un traitement des colites pseudomembraneuses? Presse Medicale 18, 1299.
    • 14. Castex F, Jouvert S, Bastide M. (1987). Visualisation par microscopie electronique a balayage du transit intestinal de Saccharomyces boulardii chez la souris. Bulletin de la Sociiti Frangaise de Mycologie Medicale 16,249-256.
    • 15. Castex F, Corthier G, Jouvert S, Elmer GW, Guibal J, Lucas F, Bastide M . (1989). Prevention of experimental pseudomembranous cecitis by Saccharomyces boulardii: topographical histology of the mucosa, bacterial counts, and analysis of toxin production. In: Dougherty SJ, Hentges DJ, Lyerly DM et al. (eds) Microecology and Therapy, Vol 19. Institute for Microbiology, Herborn-Dill, p. 241.
    • 16. Castex F, Corthier G, Jouvert S, Elmer GW, Lucas F, Bastide M. (1990). Prevention of Clostridium dzficile-induced experimental pseudomembranous colitis by Saccharomyces boulardii: a scanning electon microscopic and microbiological study. Journal of General Microbiology 136, 1085-1089.
    • 17. Cetina-Sauri G, Basto GS. (1989). Evaluacion terapeutica de Saccharomyces boulardii en niiios con diarrea aguda. Tribuna Midica 56, 1 11-1 15.
    • 18. Chapoy P. (1985). Traitement des diarrhttes aigues infantiles: essai contr6le de Saccharomyces boulardii. Annales de Pediatrie (Paris) 32,56 1-563.
    • 19. Corthier G , Dubos F, Ducluzeau R. (1986). Prevention of Clostridium dificile induced mortality in gnotobiotic mice by Saccharomyces boulardii. Canadian Journal of Microbiology 32,894896,
    • 20. Corthier G , Dubos-Ramare F, Muller MC, Mahi: S, Vernet A, Elmer GW, Rapine P, Ducluzeau R. (1990). Etude experimentale, chez les souris a flore contrblke, des moyens Ccologiquesde lutte contre la pathologie due a Clostridium dzficile. In: Rambaud J-C, Ducluzeau R (eds) Clostridium dificileassociated Intestinal Diseases. Springer-Verlag, Paris, pp. 105-1 13.
    • 21. Corthier G, Lucas R, Jouvert S, Castex F. (1992). Effect of oral Saccharomyces boulardii treatment on the activity of Clostridiurn dificile toxins in mouse digestive tract. Toxicon 30, 1583-1 589.
    • 22. Czerucka D, Nan0 JL, Bernasconi P, Rampal P. (1989). Reponse a la toxine cholerique de deux ligntes de cellules epithiliales intestinales. Effet de Saccharomyces boulardii. Gastroenterologie Clinique et Biologique 13,383-387.
    • 23. Czerucka D, Nan0 JL, Bernasconi, P, Rampal P. (1991). Rkponse aux toxines A et B de Clostridium dzficile d'une lignCe de cellules epithkliales intestinales de rat: I R D 98. Effet de Saccharomyces boulardii. Gastroenterologie Clinique et Biologique 15,22-27.
    • 24. Czerucka D, Roux I, Nan0 JL, Bernasconi P, Rampal P. (1992). In vitro, antidiarrheic effect of yeast Saccharomyces boulardii. Abstract No. 709. Gastroenterology 102, A207.
    • 25. Czerucka D, Roux I, Rampal P. (1993). The cholera toxin neutralizing factor secreted by Saccharomyces boulardii acts directly on cells. Abstract No. 1087. Gastroenterology (in press).
    • 26. Drapkin MS, Worthington MG, Chang TW, Razvi SA. (1985). Clostridium dijicile colitis mimicking acute peritonitis. Archives of Surgery 120, 1321-1322.
    • 27. Ducluzeau R, Bensaada M. (1982).Effet compare de l'administration unique ou en continu de Saccharomyces boulardii sur l'etablissement de diverses souches de candida dans le tractus digestif de souris gnotoxeniques. Annales de Microbiologie (Paris) 133,491-501.
    • 28. Dudley MN, McLaughlin JC, Carrington G, Frick J, Nightingale CH, Quintiliani R. (1986). Oral bacitracin vs vancomycin therapy for Clostridium dificile-induced diarrhea: a randomized doubleblind trial. Archives of Internal Medicine 146, 1101-1 104.
    • 29. Elmer GW, McFarland LV. (1987). Suppression by Saccharomyces boulardii of toxigenic Clostridium dificile overgrowth after vancomycin treatment in hamsters. Antimicrobial Agents and Chemotherapy 31,129-131.
    • 30. Elmer GW, Surawicz, CM, McFarland LV, Chinn J. (1989). An open trial of vancomycin plus Saccharomyces boulardii for the treatment of relapsing Clostridium dificile diarrhea/colitis. In: Dougherty SH, Hentges DJ, Lyerly DM et al. (eds),Microecology and Therapy, vol. 19. Institute for Microecology. Herborn-Dill, p. 251.
    • 31. Elmer GW, Corthier G. (1991). Modulation of Clostridium dificile induced mortality as a function of the dose and the viability of the Saccharomyces boulurdii used as a preventative agent in gnotobiotic mice. Canadian Journal of Microbiology 37,3 15-3 17.
    • 32. Fekety R, Shah AB. (1993).Diagnosisand treatment of Clostridiumdijicilecolitis. Journafofthe American Medical Association 289,71-75.
    • 33. Gerberding JL. (1989). Diagnosis and management of HIV-infected patients with diarrhoea. Journal of Antimicrobial Chemotherapy 23, Suppl. A, 83-87.
    • 34. Gerding DN. ( I 989). Disease associated with Clostridium dificile infection. Annals of Internal Medicine 110,255-257.
    • 35. Giudici HJ, Botto L, Montejo de Aramayo IA, Aramayo L. (1985).Evaluaci6nclinicadelaadministracion de Saccharomyces boulardii “Vitales” en el tratamiento de la diarrea aguda en ninos. Informe preliminar. La Semana Medica 167,254-262.
    • 36. Gorbach SL, Chang T-W, Goldin B. (1987). Successfultreatment of relapsing Clostridium dificile colitis with Lactobacillus GG. Lancet ii, 1519.
    • 37. Grillot R, Lebeau B, Goullier-Fleuret A, Chouraqui JP, Andrini P. (1986). “De deux maux il faut choisir le moindre” ou du caractere opportuniste de Saccharomyces boulardii. Abstract. Royale Societe FranGaise de Mycologie Medicale, Paris, France.
    • 38. Chenter PA, Settle RG, Perlmutter S, Marino PL, Desimone GA, Rolandelli RH. (1991). Tube feeding-related diarrhea in acutely ill patients. Xpurnal of Parenteral Enteral Nutrition 15,277-280.
    • 39. HIochter W, Chase D, Hagenhoff G. (1990).Saccharo% y e s boulardii bei akuter erwachsenendiarrhoe. Vlirksamkeit und vertraglichkeit der behandlung. Munchener Medizinische Wochenschrft132,188-192.
    • 40. Johnson S, Gerding DN, Olson MM, Weiler IUD, Hughes RA, Clabots CR, Peterson LR. ( I 990). Prospective, controlled study of vinyl glove use to interrupt Clostridium dificile nosocomial transmission. American Journal of Medicine 88, 137-140.
    • 41. Jouirou A, Jeridi A, Ben Said H, El Mabrouk J. Essoussi AS, Harbi A. (1990). Le traitement des diarrhees aigues du nourrisson: place de Saccharomyces boulardii. Maghreb Midical 229, 29-3 1.
    • 42. K.abins SA. (1975). Outbreak of clindamycinassociated colitis. Annals of Internal Medicine 83, 83&831.
    • 43. Kimmey MB, Elmer GW, Surawicz CM, McFarland LV. (1990). Prevention of further recurrences of Clostridium dificile colitis with Saccharomyces boulardii. Digestive Diseases and Sciences 35, 897-90 1.
    • 44. K.lein SM, Elmer GW, McFarland LV, Surawicz CM, Levy RH. (1993). Recovery and elimination of the biotherapeutic agent, Saccharomyces boulardii, in healthy human volunteers. Pharmaceutical Alesearch (in press).
    • 45. Kkause W, Matheis H, Wulf K. (1969). Fungaemia and funguria after oral administration of Candida albicans. Lancet i, 598-600.
    • 46. L.evecq H, Cerf H . (1992). Interst des levures et des kictobacilles dans le traitement prkventif ou curatif des diarrhkes post-antibiotiques et au cours du sida. EMC-Instantanis Mkdicaux 5,3-5.
    • 47. hlachado Caetano JA, Parames MT, Babo MJ, Santos A, Bandeira Ferreira A, Freitas AA, Clementa Coelho MR, Matthioli Mateus A. (1986). Iinmunopharmacological effects of Saccharomyces boulardii in healthy volunteers. International Journal of Immunopharmacology 8,245-249.
    • 48. h4arteau P, Pochart P, Flourie B, Pellier P, Santos L, Desjeux J-F, Rambaud J-C. (1990).Effect of chronic ingestion of a fermented dairy product containing L,actobacillusacidophilus and Bijidobacterium bijdum on metabolic activities of the colonic flora in humans. American Journal of Clinical Nutrition 52, 685-688.
    • 49. h4assot J, Desconclois M, Astoin J. (1983). Protection par Saccharomyces boulardii de la diarrhee a Escherichia coli du souriceau. Annales I'harmaceutiques FranGaises 4 0 , 4 4 5 4 9 .
    • 50. h4assot J, Sanchez 0, Couchy R, Astoin J, Parodi AL. (1984). Bakteriopharmakologische aktivitat von Saccharomyces boulardii bei der clindamycininduzierten kolitis im hamster. ArzneimittelForschung 34,794-797.
    • 51. McFarland LV, Mulligan ME, Kwok RYY, Stamm WE. (1989). Nosocomial acquisition of Clostridium d@cile infection. New England Journal of Medicine 320,204-2 10.
    • 52. McFarland LV, Surawicz C M , Stamm WE. (1990). Risk factors for Clostridium dzjicile carriage and C. di@cile-associated diarrhea in a cohort of hospitalized patients. Journal of Injkctious Diseases 162,678-684.
    • 53. McFarland LV. (1991). The epidemiology of Clostridium diflcile infections. Gustroenterology International 4,82-85.
    • 54. McFarland LV, Surawicz CM, Elmer G W , Moyer KA, Melcher SA, Greenberg R, Bowen K. (1993). Multivariate analysis of the clinical efficacy of a biotherapeutic agent, Saccharomyces boulardii, for the prevention of antibiotic-associated diarrhea. Abstract No. 148.American JournalofEpidemiology (in press).
    • 55. Mulligan ME, Citron D, Gabay E, Kirby B, George WL, Finegold SM. (1984). Alterations in human fecal flora, including ingrowth of Clostridium dzficile, related t o cefoxitin therapy. Antimicrobial Agents and Chemotherapy 26,343-346.
    • 56. Pierce PF, Wilson R, Silva J, Garagusi VF, Rifkin D, Fekety R, Nunez-Montiel 0, Dowell VR, Hughes JM. (1982). Antibiotic associated pseudomembranous colitis: an epidemiologic investigation of a cluster of cases. Journal of Infectious Diseases 145,169-174.
    • 57. Pothoulakis C, Kelly CP, Joshi MA, G a o N, O'Keane CJ, Castagliuolo I, LaMont JT. (1993). Saccharomyces boulardii inhibits Clostridium dificile toxin A binding and enterotoxicity in rat ileum. Gastroenterology (in press).
    • 58. Rao SSC, Edwards CA, Austen CJ, Bruce C, Read NW. (1988). Impaired colonic fermentation of carbohydrate after ampicillin. Gastroenterology 94, 928-932.
    • 59. Read NW. (1982). Diarrhoea: the failure of colonic salvage. Lancet ii, 481-483.
    • 60. Rigothier MC, Maccario J, Vuong PN, Gayral P. ( 1990). Effets des levures Saccharomyces boulardii sur les trophozoites d'Entamoeba histolytica in vitro et dans l'amibiase caecale du jeune rat. Annales dr Parasitologie Humaine et Comparte 65,5 1-60.
    • 61. Saint-Marc T, Rossello-Prats L, Touraine JL. (1991). Efficacitk de Saccharomyces boulardii dans le traitement des diarrhees du SIDA. Annales de Medecine Interne (Paris) 142,6465.
    • 62. Schlotterer M, Bernasconi P, Lebreton F, Wassermann D. (1987). Interkt de Saccharomyces boulardii dans la tolerance digestive de la nutrition entkrale a debit continu chez le brQIC. Nutrition Clinique et MCtabolisme 1,31-34.
    • 63. Siitonen S, Vapaatalo H, Salminen S, Gordin A, Saxelin M, Wikberg R, Kirkkola A-L. (1990). Effect of Lactobacillus GG yoghurt in prevention of antibiotic associated diarrhoea. Annals of Medicine 22, 57-59.
    • 64. Smith CE, Marien L, Brogdon C, Faust-Wilson P, Lohr G , Gerald K B , Pingleton S. (1990). Diarrhea associated with tube feeding in mechanically ventilated critically ill patients. Nursing Research 39, 148-152.
    • 65. Surawicz C M , Elmer GW, Speelman P, McFarland LV, Chinn J, Van Belle G. (1 988). A clinical trial to test the ability of Saccharomyces boulardii to prevent antibiotic associated diarrhoea. In: Bokkenheuser VD, Borriello SP, Donelli G etal. (eds) Microecology and Therapy, vol. 18. Institute for Microecology, Herborn-Dill, p. 113.
    • 66. Surawicz CM, McFarland LV, Elmer G , Chinn J. (1989). Treatment of recurrent Clostridium dijicile colitis with vancomycin and Saccharomyces boulurdii. American Journal of Gastroenterology 84, 1285-1287.
    • 67. Surawicz CM, Elmer GW, Speelman P, McFarland LV, Chinn J, Van Belle G . (1989). Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology 96, 98 1-988.
    • 68. Surawicz C M , Greenberg R, Fekety R, McFarland LV, Moyer K, Bowen K, Cox J, Noorani Z, Elmer GW. ( 1 993). Saccharomyces boulardii prevents recurrent C. dzflcile pseudomembranous colitis and diarrhea: a multicenter controlled trial. Abstract No. 57-0015 . Gastroenterology (in press).
    • 69. Tankanow RM, Ross MB, Ertel IJ, Dickinson DG, McCormick LS, Garfinkel JF. (1990). A doubleblind, placebo-controlled study of the efficacy of lactinex in the prophylaxis of amoxicillin-induced diarrhea. DICP, The Annals o f Pharmacotherapy 24, 382-384.
    • 70. Teasley PG, Gerding DN, Olson MM, Peterson LR, Gebhard RL, Schwartz MJ, Lee J T Jr. (1983). Prospective randomized trial of metronidazole versus vancomycin for Clostridium dijicile-associated diarrhea and colitis. Lancet ii, 1043-1046.
    • 71. Tedesco RJ, Barton RW, Alpers D H . (1974). Clindamycin-associated colitis. Annals o f Internal Medicine 81,429-433.
    • 72. Tempe JD, Steidel AL, Blehaut H, Hasselmann M, Lutun PH, Maurier F. (1983). Prevention par Saccharomyces boulardii des diarrhees de I'alimentation entkrale a debit continu. La Semaine des H6pitaux de Paris 59, 1409-1 4 12.
    • 73. Toothaker RD, Elmer G W . (1984). Prevention of clindamycin-induced mortality in hamsters by Saccharomyces boulardii. Antimicrobial Agents and Chemotherapy 26,552-556.
    • 74. Van der Waaij D, Horstra H, Wiegersma N. (1982). Effect of &lactam antibiotics o n the resistance of the digestive tract of mice to colonization. Journal qf' Infectious Diseases 146,417422.
    • 75. Vidon N, Huchet B, Rambaud JC. (1986). Influence de Saccharomyces boulardii sur la secretion jejunale induite chez le rat par la toxine cholerique. Custrnenterologie Clinique et Biologiqur 10,13-16.
    • 76. Vincent P, Colombel JF, Lescut D, Fournier L, Savage C, Cortot A, Quandalle P, Vankemmel M, Leclerc H. (1988). Bacterial translocation in patients with colorectal cancer. Journalof'lnfecrious Diseases 158,1395-1396.
    • 77. Wilmore DW. (1974). Nutrition and metabolism following thermal injury. Clinics in Plastic Surgery 1,603.
    • 78. Zunic P, Lacotte J, Pegoix M, Buteux G, Leroy G , Mosquet B, Moulin M. (1991). Fongemie a SLrccharomyces boulardii. A propos d'un cas (letter). Therapir 46,498-499.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article

Collected from